File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Scopus: eid_2-s2.0-0036110365
- PMID: 11962758
- WOS: WOS:000174935900021
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Natural killer cell malignancies: Clinicopathologic and molecular features
Title | Natural killer cell malignancies: Clinicopathologic and molecular features |
---|---|
Authors | |
Keywords | CD56 Leukemia Lymphoma Natural killer cell |
Issue Date | 2002 |
Publisher | Histology and Histopathology. The Journal's web site is located at http://www.hh.um.es |
Citation | Histology And Histopathology, 2002, v. 17 n. 2, p. 539-554 How to Cite? |
Abstract | Malignancies of natural killer (NK) cells have increasingly been recognized as distinct clinicopathological entities. The tumor cells are characterized by an immunophenotype of CD2+, surface CD3-, cytoplasmic CD3ε+, and CD56+. The T cell receptor gene is in germline configuration, and a consistent association with Epstein-Barr virus is demonstrable. Pathologically, the tumor cells show variable cytological appearances, with frequent angioinvasion and angiocentricity associated with zonal necrosis. Clinically, most cases affect the nasal cavity or other parts of the upper aerodigestive tract, and are referred to as nasal NK cell lymphoma. A minority involve extranasal sites such as the skin, gastrointestinal tract and testis, and are often referred to as extranasal NK cell lymphoma. A particularly aggressive form presents fulminantly as disseminated disease, sometimes with a leukemic phase, and is referred to as aggressive NK cell lymphoma/leukemia. Cytogenetic and molecular analysis have shown DNA losses at chromosomes 6q, 11q, 13q and 17p to be recurrent aberrations in NK cell malignancies. Frequent DNA gains are also found in chromosomes 1p, 6p, 11q, 12q, 17q, 19p, 20q, and Xp. These regions of DNA losses and gains should be targets for further investigation in order to understand the molecular pathogenesis of this lymphoma. Finally, optimal treatment modalities need to be determined, as all subtypes of NK cell malignancies are associated with a poor prognosis. |
Persistent Identifier | http://hdl.handle.net/10722/77799 |
ISSN | 2023 Impact Factor: 2.5 2023 SCImago Journal Rankings: 0.571 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Siu, LLP | en_HK |
dc.contributor.author | Chan, JKC | en_HK |
dc.contributor.author | Kwong, YL | en_HK |
dc.date.accessioned | 2010-09-06T07:35:51Z | - |
dc.date.available | 2010-09-06T07:35:51Z | - |
dc.date.issued | 2002 | en_HK |
dc.identifier.citation | Histology And Histopathology, 2002, v. 17 n. 2, p. 539-554 | en_HK |
dc.identifier.issn | 0213-3911 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/77799 | - |
dc.description.abstract | Malignancies of natural killer (NK) cells have increasingly been recognized as distinct clinicopathological entities. The tumor cells are characterized by an immunophenotype of CD2+, surface CD3-, cytoplasmic CD3ε+, and CD56+. The T cell receptor gene is in germline configuration, and a consistent association with Epstein-Barr virus is demonstrable. Pathologically, the tumor cells show variable cytological appearances, with frequent angioinvasion and angiocentricity associated with zonal necrosis. Clinically, most cases affect the nasal cavity or other parts of the upper aerodigestive tract, and are referred to as nasal NK cell lymphoma. A minority involve extranasal sites such as the skin, gastrointestinal tract and testis, and are often referred to as extranasal NK cell lymphoma. A particularly aggressive form presents fulminantly as disseminated disease, sometimes with a leukemic phase, and is referred to as aggressive NK cell lymphoma/leukemia. Cytogenetic and molecular analysis have shown DNA losses at chromosomes 6q, 11q, 13q and 17p to be recurrent aberrations in NK cell malignancies. Frequent DNA gains are also found in chromosomes 1p, 6p, 11q, 12q, 17q, 19p, 20q, and Xp. These regions of DNA losses and gains should be targets for further investigation in order to understand the molecular pathogenesis of this lymphoma. Finally, optimal treatment modalities need to be determined, as all subtypes of NK cell malignancies are associated with a poor prognosis. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Histology and Histopathology. The Journal's web site is located at http://www.hh.um.es | en_HK |
dc.relation.ispartof | Histology and Histopathology | en_HK |
dc.subject | CD56 | - |
dc.subject | Leukemia | - |
dc.subject | Lymphoma | - |
dc.subject | Natural killer cell | - |
dc.subject.mesh | Animals | en_HK |
dc.subject.mesh | Cell Lineage | en_HK |
dc.subject.mesh | Diagnosis, Differential | en_HK |
dc.subject.mesh | Humans | en_HK |
dc.subject.mesh | Immunophenotyping | en_HK |
dc.subject.mesh | Killer Cells, Natural - immunology - pathology | en_HK |
dc.subject.mesh | Leukemia | en_HK |
dc.subject.mesh | Lymphoma - diagnosis - immunology - pathology | en_HK |
dc.subject.mesh | Lymphoproliferative Disorders | en_HK |
dc.subject.mesh | Prognosis | en_HK |
dc.subject.mesh | Receptors, Immunologic - immunology | en_HK |
dc.subject.mesh | Receptors, KIR | en_HK |
dc.title | Natural killer cell malignancies: Clinicopathologic and molecular features | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0213-3911&volume=17&spage=539&epage=54&date=2002&atitle=Natural+killer+cell+malignancies:+clinicopathologic+and+molecular+features | en_HK |
dc.identifier.email | Kwong, YL:ylkwong@hku.hk | en_HK |
dc.identifier.authority | Kwong, YL=rp00358 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.pmid | 11962758 | - |
dc.identifier.scopus | eid_2-s2.0-0036110365 | en_HK |
dc.identifier.hkuros | 107998 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0036110365&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 17 | en_HK |
dc.identifier.issue | 2 | en_HK |
dc.identifier.spage | 539 | en_HK |
dc.identifier.epage | 554 | en_HK |
dc.identifier.isi | WOS:000174935900021 | - |
dc.publisher.place | Spain | en_HK |
dc.identifier.scopusauthorid | Siu, LLP=35574705900 | en_HK |
dc.identifier.scopusauthorid | Chan, JKC=7403287069 | en_HK |
dc.identifier.scopusauthorid | Kwong, YL=7102818954 | en_HK |
dc.identifier.issnl | 0213-3911 | - |